Plasma Collection Machines (PCM) Market Size, Share & Trends Analysis Report By Product (Desk Type Plasma Collection Machine (PCM), Trolley Type Plasma Collection Machine (PCM)), By Applications (Hospitals, Blood Center, Others), By End Use, By Region, and Segment Forecasts - 2035

Plasma Collection Machines (PCM) Market Overview

plasma collection machines (pcm) market size was valued at USD 374.62 million in 2025 and is poised to grow from USD 386.61 million in 2026 to USD 517.23 million by 2035, growing at a CAGR of 3.2% during the forecast period (2026-2035). 

The Plasma Collection Machines (PCM) Market supports global plasma collection for therapies, immunoglobulin production, and transfusion needs. Annually, more than 70 million liters of plasma are collected worldwide. According to recent data, PCM and related plasmapheresis devices now underpin an increasing share of that collection volume, as total licensed plasma donation centers globally exceeded 1,000 by 2023. The market plays a critical role in enabling over 16.5 million recipients of plasma-derived protein therapies in recent years. Demand from chronic disease, hemophilia, immunodeficiency, and neurological disorder treatments fuels the need for reliable PCM infrastructure.

In the United States, the PCM Market is deeply entrenched: the U.S. hosts roughly 950+ plasma donation centers, contributing to more than 65% of global source plasma collection. Plasma collections in the U.S. increased by approximately 250% between 2009 and 2019, reflecting rapid expansion of centers and acquisition of automated PCM equipment. Over 50 million plasmapheresis procedures were reportedly performed across the U.S. and Canada in a recent year, with a substantial portion conducted in U.S. donation centers. The dominance of U.S.-based centers underlines PCM demand and infrastructure strength for domestic and export-oriented plasma supply.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver: Rising demand for plasma-derived therapies — with global plasma donation volume exceeding 70 million liters annually and immunoglobulin therapies used by over 16.5 million patients worldwide.
• Major Market Restraint: High capital and operational costs — a portion of small centers cite machine cost and consumables burden as limiting expansion.
• Emerging Trends: Automated and multi-procedure PCM machines — about 2,800 units now capable of plasma exchange, photopheresis, and other apheresis procedures worldwide.
• Regional Leadership: North America accounts for roughly 41% of global plasmapheresis device deployment, followed by Europe (~28%) and Asia-Pacific (~22%) in recent device distribution data.
• Competitive Landscape: A handful of leading PCM providers dominate — key players supply the majority of machines across donation centers, creating a concentrated competitive environment.
• Market Segmentation: Blood centers account for approximately 55% of plasma collection device deployments globally, while hospitals and therapeutic centers constitute the remainder.
• Recent Development: Over 12 million biodegradable disposable kits were manufactured in 2024 for PCM systems, reducing environmental footprint by nearly 1,900 metric tons.

Plasma Collection Machines (PCM) Market Latest Trends

The Plasma Collection Machines (PCM) Market is evolving rapidly in response to rising demand for plasma-derived therapies and technological advancements. As of 2024, approximately 42,000 PCM units are connected to donor management systems globally, enabling about 64 million donation sessions. Among these machines, roughly 19,000 integrate remote diagnostics, which has reduced downtime by 31%, improving operational efficiency and donor throughput. Meanwhile, 2,800 modular units supporting multi-procedure capability — including plasma exchange, photopheresis, and LDL apheresis — have expanded the scope of plasma collection beyond standard donation.

Portable and lightweight PCM devices — under 20 kg — now number over 7,500, increasingly deployed in mobile clinics, ambulances, and ICU settings, enabling plasma collection outside traditional fixed centers. These portable machines offer priming times under 7 minutes, facilitating rapid donor intake and streamlined workflows. Dual-needle collection systems are also becoming widely adopted; approximately 12,400 units now in use have improved collection efficiency by 22%, reducing donor chair-time and increasing plasma yield per session.

Plasma Collection Machines (PCM) Market Dynamics

DRIVER

Rising demand for plasma-derived therapies and increasing global plasma collection volume

Globally, over 70 million liters of plasma are collected per year, underpinning the production of immunoglobulins, clotting factors, albumin, and hyper-immune treatments. The growing prevalence of chronic diseases, immunodeficiencies, autoimmune disorders, and neurological conditions has elevated the demand for plasma-derived therapies. In 2022 alone, more than 16.5 million patients worldwide received plasma-derived protein treatments. As reliance on plasma-based therapeutics intensifies, donation centers need to scale capacity, prompting acquisition of modern PCM units. The sheer volume of required plasma — along with frequent donor cycles allowed (some systems permit donation up to twice a week per donor) — drives increased demand for reliable, high-throughput plasma collection machines globally.

As more countries expand plasma collection infrastructure, and as regulatory bodies relax or refine policies, donation centers are scaling up operations. For B2B stakeholders and procurement managers, this dynamic represents a stable and growing base of demand — ensuring that investments in PCM devices are matched by need. The push for higher plasma availability worldwide directly translates into expanding PCM Market utilization, encouraging manufacturers to supply advanced apheresis and collection systems to meet global health demands.

RESTRAINT

High capital expenditure and operational costs limit adoption among small centers

Despite strong demand, many small and mid-sized donation centers and hospitals face significant financial barriers to adopting advanced PCM units. High initial capital costs for automated or modular collection machines — along with expensive single-use disposable kits — create budget constraints. For example, even though more than 12 million disposable kits were produced in 2024, their recurring cost remains a substantial ongoing operating expense for centers. Additionally, maintenance, calibration, consumables, and compliance with stringent safety protocols add to operational burdens.

Centers in regions with low donation volume may find the cost-per-liter of collected plasma prohibitively high, limiting cost-effectiveness. As a result, only larger, well-funded centers or networks of donation centers tend to invest in advanced PCM equipment. Small clinics or community blood centers often continue with outdated or manual systems, which yield lower efficiency and throughput. This economic divide restrains uniform adoption and creates unequal access to modern plasma collection services across regions.

OPPORTUNITY

Expansion into emerging markets with underdeveloped plasma collection infrastructure

Many emerging markets — especially in Asia, Latin America, the Middle East, and Africa — remain under-penetrated in terms of plasma collection infrastructure. These regions often lack sufficient licensed donation centers or automated PCM equipment. With global plasma demand rising, there is a clear opportunity for investment in new PCM deployment. Establishing modern plasma donation centers in these regions can tap into large populations, increasing donor pools and enabling local production of plasma-derived therapies.

Given that recent data show global plasma collections rising and donation centers expanding by over 25% globally since 2021, there is significant whitespace in under-served geographies. Deploying lightweight, portable, and cost-effective PCM machines can lower entry barriers. Also, modular multi-procedure units support flexibility — serving in therapeutic plasma collection, exchange, or photopheresis — making them attractive to new centers aiming to maximize utilization. For investors and PCM manufacturers targeting emerging markets, this represents a high-growth opportunity to capture early market share, build donor networks, and support local healthcare infrastructure.

CHALLENGE

Regulatory scrutiny, donor dependency and supply chain constraints hamper scalability

While demand and opportunity exist, PCM Market growth is challenged by regulatory complexities, donor dependency, and supply chain limitations. Many countries impose strict regulations on plasma donation frequency, donor eligibility, donor compensation, and safety screening. These constraints can limit donor availability and reduce the number of collection sessions per donor. For example, compliance requirements — including sterile disposable kit use, cold chain for plasma storage, and traceability — raise operational complexity, particularly in regions with limited infrastructure.

Additionally, dependence on paid or compensated donors (especially in high-income countries) raises ethical concerns and may lead to donor fatigue or supply volatility. Occurrences such as global health emergencies or regulatory changes can disrupt donor supply, impacting PCM usage rates. Supply chain disruptions for disposable kits or spare parts for PCM devices can also restrict operations. Collectively, these challenges can hinder the scale-up of PCM deployment in new and existing centers, affecting market growth and stability.

Segmentation Analysis

The Plasma Collection Machines (PCM) Market can be segmented by Type and Application, reflecting different usage settings and equipment configurations. By Type, the market includes Desk Type and Trolley Type PCM machines; by Application, it covers Hospitals, Blood Centers, and Others (mobile clinics, emergency care units, small clinics). These segments together define where and how PCM devices are deployed and their relative prevalence.

By Type

Desk Type Plasma Collection Machine (PCM)

The Desk Type Plasma Collection Machine segment is estimated to hold a market size of USD 225.41 million in 2025, representing 58.3% share, expected to reach USD 301.23 million by 2034 with a steady 3.2% CAGR, driven by rising plasma donation activities.

Top 5 Major Dominant Countries in the Desk Type Segment

• United States:The United States Desk Type PCM segment is projected to reach USD 82.65 million in 2025, capturing 36.7% share, increasing to USD 112.78 million by 2034, supported by 3.3% CAGR and expanding plasma collection networks nationwide.
• China:China’s Desk Type PCM market is valued at USD 38.21 million in 2025, holding 16.9% share, expected to grow to USD 51.43 million by 2034 at around 3.4% CAGR, driven by high donor participation growth.
• Germany:Germany accounts for USD 19.74 million in 2025, representing 8.7% share, anticipated to expand to USD 26.13 million by 2034 with 3.1% CAGR, supported by strong medical infrastructure investments.
• Japan:Japan’s Desk Type PCM segment is estimated at USD 17.58 million in 2025, accounting for 7.8% share, projected to reach USD 23.39 million by 2034 through 3.0% CAGR, backed by rising clinical plasma usage.
• United Kingdom:The United Kingdom holds USD 14.95 million in 2025, equal to 6.6% share, forecasted to reach USD 19.85 million by 2034 with 3.2% CAGR, driven by modernization of blood service centers.

Trolley Type Plasma Collection Machine (PCM)

The Trolley Type PCM segment is estimated to achieve USD 161.20 million in 2025, holding 41.7% share, projected to reach USD 215.99 million by 2034 with a stable 3.2% CAGR, favored for mobility and flexible deployment.

By Application

Hospitals

Hospital applications account for USD 179.50 million in 2025, holding 46.4% share, expected to reach USD 240.18 million by 2034 with 3.2% CAGR, driven by increased plasma-based therapeutic procedures.

Top 5 Major Dominant Countries in Hospital Application

• United States:The U.S. hospital application market stands at USD 65.42 million in 2025, representing 36.4% share, projected to rise to USD 87.60 million by 2034 with 3.3% CAGR, supported by high-volume therapeutic plasma demand.
• China:China’s hospital PCM market totals USD 29.36 million in 2025, with 16.3% share, expected to reach USD 39.08 million by 2034 at 3.4% CAGR, driven by rapid expansion of tertiary care hospitals.
• Germany:Germany holds USD 14.95 million in 2025, capturing 8.3% share, set to reach USD 19.42 million by 2034 supported by 3.1% CAGR, as advanced plasma therapy adoption increases.
• Japan:Japan contributes USD 13.46 million in 2025, representing 7.5% share, forecasted to rise to USD 17.33 million by 2034 with 3.0% CAGR, driven by widening donor integration programs.
• United Kingdom:The United Kingdom totals USD 11.16 million in 2025, making 6.2% share, projected to grow to USD 14.41 million by 2034 with 3.2% CAGR, supported by stronger hospital transfusion services.

Blood Centers

Blood Centers account for USD 145.94 million in 2025, representing 37.8% share, and are expected to reach USD 194.96 million by 2034 with 3.2% CAGR, reflecting rising donor frequency and plasma extraction requirements.

Regional Outlook

North America

North America accounts for USD 157.51 million in 2025, representing 40.7% share, expected to reach USD 210.82 million by 2034 with 3.3% CAGR, supported by large donor pools and advanced plasma processing infrastructure.

North America – Major Dominant Countries

• United States:The United States holds USD 143.21 million in 2025, securing 90.9% share, projected to reach USD 193.13 million by 2034 with 3.3% CAGR, driven by extensive commercial plasma collection programs.
• Canada:Canada stands at USD 10.28 million in 2025, representing 6.5% share, expected to reach USD 13.49 million by 2034 with 3.1% CAGR, supported by growing clinical plasma usage.
• Mexico:Mexico totals USD 4.02 million in 2025, around 2.6% share, increasing to USD 5.41 million by 2034 with 3.2% CAGR, driven by strengthening blood donation frameworks.
• Bahamas:The Bahamas market is USD 0.12 million in 2025, with 0.08% share, projected to reach USD 0.16 million by 2034 at 3.0% CAGR, supported by incremental healthcare modernization.
• Cuba:Cuba records USD 0.09 million in 2025, nearly 0.06% share, expected to rise to USD 0.12 million by 2034 with 3.1% CAGR, reflecting growing public health initiatives.

Europe

Europe reaches USD 108.68 million in 2025, making 28.1% share, forecasted to reach USD 145.49 million by 2034 with 3.1% CAGR, driven by structured donor programs and strong medical device regulations.

Europe – Major Dominant Countries

• Germany:Germany holds USD 33.52 million in 2025, achieving 30.8% share, projected to reach USD 44.46 million by 2034 with 3.1% CAGR, supported by high operational efficiency in plasma networks.
• United Kingdom:The U.K. segment totals USD 21.24 million in 2025, capturing 19.5% share, expected to reach USD 27.95 million by 2034 at 3.2% CAGR, driven by collection modernization.
• France:France represents USD 17.39 million in 2025, holding 16% share, projected to hit USD 23.07 million by 2034 with 3.1% CAGR, backed by national transfusion services.
• Italy:Italy posts USD 14.62 million in 2025, equal to 13.4% share, anticipated to reach USD 19.13 million by 2034 with 3.0% CAGR, supported by rising donor participation rates.
• Spain:Spain records USD 12.42 million in 2025, representing 11.4% share, expected to grow to USD 16.28 million by 2034 at 3.1% CAGR, driven by expanding regional donor programs.

Asia

Asia accounts for USD 87.43 million in 2025, representing 22.6% share, expected to reach USD 119.79 million by 2034 with 3.4% CAGR, fueled by rapidly expanding healthcare systems and rising plasma therapy demand.

Asia – Major Dominant Countries

• China:China holds USD 47.73 million in 2025, equal to 54.6% share, expected to reach USD 65.39 million by 2034 with 3.4% CAGR, driven by large-scale donor registration and infrastructure development.
• Japan:Japan totals USD 26.92 million in 2025, accounting for 30.8% share, forecasted to reach USD 35.07 million by 2034 with 3.0% CAGR, reflecting advanced medical technology adoption.
• India:India contributes USD 7.02 million in 2025, representing 8% share, projected to grow to USD 10.02 million by 2034 with 4.0% CAGR, supported by rising healthcare investments.
• South Korea:South Korea stands at USD 3.42 million in 2025, with 3.9% share, expected to hit USD 4.68 million by 2034 at 3.3% CAGR, driven by improved blood center operations.
• Thailand:Thailand holds USD 2.34 million in 2025, about 2.7% share, expected to reach USD 3.28 million by 2034 with 3.6% CAGR, benefiting from strengthened donor engagement programs.

Middle East and Africa

MEA region totals USD 32.98 million in 2025, equal to 8.5% share, projected to reach USD 41.13 million by 2034 with 2.5% CAGR, driven by gradual improvements in healthcare access and donor awareness.

Middle East and Africa – Major Dominant Countries

• Saudi Arabia:Saudi Arabia accounts for USD 7.94 million in 2025, representing 24.1% share, expected to reach USD 10.16 million by 2034 with 2.6% CAGR, driven by advanced plasma collection infrastructure.
• United Arab Emirates:UAE totals USD 5.48 million in 2025, holding 16.6% share, expected to increase to USD 7.08 million by 2034 at 2.7% CAGR, with strong healthcare modernization.
• South Africa:South Africa records USD 4.72 million in 2025, around 14.3% share, anticipated to reach USD 5.86 million by 2034 through 2.4% CAGR, supported by increased donor mobilization.
• Egypt:Egypt’s market stands at USD 3.26 million in 2025, making 9.9% share, projected to hit USD 3.98 million by 2034 with 2.2% CAGR, driven by public hospital upgrades.
• Nigeria:Nigeria totals USD 2.13 million in 2025, covering 6.5% share, expected to reach USD 2.61 million by 2034 at 2.1% CAGR, reflecting incremental improvements in donor programs.

List of Top Plasma Collection Machines (PCM) Companies

• Terumo BCT — recognized as a leading global PCM manufacturer with one of the highest installed base counts across donation centers worldwide, supplying a large portion of the approximately 42,000 donor-management connected devices.
• Haemonetics — among the top two companies globally, providing a significant share of automated plasmapheresis and plasma collection machines used in both blood centers and hospital settings.
• Fresenius Kabi
• Asahi Kasei Medical
• Nikkiso
• Braun
• Miltenyi Biotec
• Kaneka Medix
• Nigale
• Haier Biomedical
• Scinomed
• Medica SPA
• Shanghai Dahua Medical Equipment

Investment Analysis and Opportunities

For investors, the Plasma Collection Machines (PCM) Market presents substantial opportunities owing to rising global demand for plasma-derived therapies and shortfalls in plasma supply infrastructure in many countries. With over 70 million liters of plasma collected annually worldwide and immunoglobulin treatments reaching more than 16.5 million patients, there is stable and growing demand for plasma collection capacity. Investments targeting emerging markets — particularly in Asia-Pacific, Middle East & Africa — where PCM penetration remains low but demand for plasma therapies is rising, offer high growth potential.

Deploying portable trolley-type PCM machines in underserved regions can reduce infrastructure barriers and expand donor reach. The growing number of licensed plasma donation centers (over 1,000 globally by 2023) implies room for establishment of new centers; financing these centers combined with PCM equipment procurement can deliver long-term returns. Furthermore, demand for multi-procedure modular PCM units (supporting exchange, photopheresis, and standard plasma collection) provides opportunities for equipment providers to offer versatile systems maximizing utilization and profitability.

New Product Development

Innovation in the Plasma Collection Machines (PCM) Market is accelerating, focusing on donor safety, operational efficiency, and flexibility. Recent new-generation PCM systems integrate remote diagnostics and donor-management connectivity: roughly 19,000 of the 42,000 connected devices feature remote monitoring, enabling real-time device health tracking and reducing downtime by about 31%. This results in more reliable donation sessions and reduced maintenance costs for operators.

Portable, trolley-type PCM units have gained traction: over 7,500 lightweight devices (under 20 kg) are now deployed globally for mobile blood donation drives, rural clinics, and emergency response units. These units have priming times under 7 minutes, improving throughput and reducing donor chair-time. Dual-needle collection systems have increased significantly — about 12,400 units now deployed — enhancing plasma yield per donor and reducing time per session by up to 22% over older single-needle systems.

Modular multi-procedure PCM machines, numbering around 2,800 units, support not only plasma collection but also therapeutic plasma exchange, photopheresis, and LDL apheresis. This versatility allows blood centers and hospitals to maximize usage across different treatment types, improving equipment utilization rates. Enhanced user interfaces with touchscreens, voice-guidance, and cloud-based donor tracking have been implemented in about 27,000 PCM devices, reducing operator training time by nearly 26%. These technological innovations position PCM providers to meet rising global plasma demand, support mobile and remote collection needs, and offer scalable solutions for both established and emerging markets.

Five Recent Developments (2023–2025)

1. By 2024, global deployment reached approximately 42,000 PCM units connected to donor management systems, enabling around 64 million donation sessions
2. Manufacturers produced over 12 million biodegradable disposable kits in 2024, leading to a reduction of about 1,900 metric tons in medical waste compared to previous years.
3. Over 7,500 portable/trolley-type PCM machines (under 20 kg) were deployed globally by 2025, expanding plasma collection capacity in mobile clinics, rural areas, and emergency units.
4. Around 2,800 modular PCM units capable of plasma exchange, photopheresis, and LDL apheresis entered service between 2023 and 2025, broadening therapeutic capabilities of donation centers.
5. Implementation of remote diagnostics and cloud-enabled donor management features in about 19,000 machines reduced device downtime by 31%, improving operational efficiency and throughput.

Report Coverage of Plasma Collection Machines (PCM) Market

This Plasma Collection Machines (PCM) Market Report delivers a comprehensive analysis of global and regional plasma collection device deployment, market segmentation by type (desk and trolley) and application (hospitals, blood centers, others), and current technological developments shaping the market. It examines trends such as adoption of portable devices, modular multi-procedure units, and automation in donor management systems, along with the production of disposable kits and environmental impact mitigation.

The report provides insights into regional distribution: North America remains dominant with tens of thousands of plasmapheresis devices and donation centers; Europe follows with widespread coverage across 31 countries; Asia-Pacific shows rapid growth backed by large donor bases; and Middle East & Africa enters with early-stage but increasing PCM adoption. Competitive landscape analysis identifies top PCM equipment providers and highlights concentration among major companies. Investment analysis outlines opportunities for deployment in emerging markets and expansion of blood center networks. New product development coverage includes portable units, modular machines, and digital connectivity features. Five recent developments are documented to show momentum and innovation from 2023 to 2025.